Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.30 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2892232 | 0.80 | CSNK2A1 (0.36) | CSNK2A1NPSR1CSNK2A2CSNK2B | |
| SCHEMBL5636248 | 0.74 | L3MBTL1 (0.31) | — | |
| SCHEMBL12173291 | 0.70 | CSNK2A1 (0.31) | CSNK2A1NPSR1CSNK2A2CSNK2B | |
| SCHEMBL12764905 | 0.68 | L3MBTL1 (0.31) | CSNK2A1NPSR1CSNK2A2CSNK2B | |
| SCHEMBL5484856 | 0.68 | CSNK2A1 (0.30) | CSNK2A1NPSR1CSNK2A2CSNK2B | |
| SCHEMBL12173309 | 0.67 | — | — | |
| SCHEMBL12438043 | 0.65 | — | — | |
| SCHEMBL11334722 | 0.65 | — | — | |
| SCHEMBL11690249 | 0.64 | L3MBTL1 (0.42) | — | |
| SCHEMBL12173288 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150287953-A1 | TRANSPARENT ELECTRODE, ELECTRONIC DEVICE, AND ORGANIC ELECTROLUMINESCENT ELEMENT | Konica Minolta, Inc. (JP) | 2015-10-08 | — | — | US | disclosed |
| US-9139512-B2 | Absorbent solution containing a degradation inhibitor derived from a triazole or from a tetrazole and method of absorbing acid compounds contained in a gaseous effluent | IFP Energies Nouvelles (FR) | 2015-09-22 | — | — | US | disclosed |
| EP-2217577-B1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES INC (US) | 2014-08-06 | — | — | EP | disclosed |
| WO-2012173850-A1 | BICYCLO (3.1.0) HEXANE- 2, 6 -DICARBOXYLIC ACID DERIVATIVES AS MGLU2 RECEPTOR AGONIST | ELI LILLY AND COMPANY (US) | 2012-12-20 | — | — | WO | disclosed |
| US-20120232285-A1 | Sulfonyl-1,2,4-triazole salts | UNIVERSITE DE MONTREAL (CA) | 2012-09-13 | — | — | US | disclosed |
| US-20120232285-A1 | Sulfonyl-1,2,4-triazole salts | UNIVERSITE DE MONTREAL (CA) | 2012-09-13 | — | — | US | disclosed |
| US-20120148463-A1 | ABSORBENT SOLUTION CONTAINING A DEGRADATION INHIBITOR DERIVED FROM A TRIAZOLE OR FROM A TETRAZOLE AND METHOD OF ABSORBING ACID COMPOUNDS CONTAINED IN A GASEOUS EFFLUENT | IFP Energies Nouvelles (FR) | 2012-06-14 | — | — | US | disclosed |
| US-20110178306-A1 | Sulphonyl-1,2,4-Triazole Salts | PHOSTECH LITHIUM INC. (CA) | 2011-07-21 | — | — | US | disclosed |
| US-20110178306-A1 | Sulphonyl-1,2,4-Triazole Salts | PHOSTECH LITHIUM INC. (CA) | 2011-07-21 | — | — | US | disclosed |
| US-7919629-B2 | Sulphonyl-1,2,4-triazole salts | PHOSTECH LITHIUM INC. (CA) | 2011-04-05 | — | — | US | disclosed |
| US-20090292105-A1 | SULPHONYL-1,2,4-TRIAZOLE SALTS | PHOSTECH LITHIUM INC. (CA) | 2009-11-26 | — | — | US | disclosed |
| WO-2007068822-A2 | SULPHONYL-1,2,4-TRIAZOLE SALTS | PHOSTECH LITHIUM INC. (CA) | 2007-06-21 | — | — | WO | disclosed |
| US-RE35754-E | FOR TREATING BACTERIAL INFECTIONS | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-03-24 | — | — | US | disclosed |
| US-5710146-A | ANTIBIOTICS FOR BACTERICIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-01-20 | — | — | US | disclosed |
| US-5089490-A | Cephem derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-02-18 | — | — | US | disclosed |
| US-4758556-A | Cephem derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-07-19 | — | — | US | disclosed |
| US-4278793-A | ANTIBIOTICS, BACTERICIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178306-A1 | Sulphonyl-1,2,4-Triazole Salts | TST, STS, SQOR | CSNK2A1 1541/4885NPSR1 3409/4885CSNK2A2 1481/4885 |
| US-20090292105-A1 | SULPHONYL-1,2,4-TRIAZOLE SALTS | TST, STS, SQOR | CSNK2A1 1541/4885NPSR1 3409/4885CSNK2A2 1481/4885 |
| US-20120232285-A1 | Sulfonyl-1,2,4-triazole salts | STS, TST, FIS1 | CSNK2A1 1747/4885NPSR1 2758/4885CSNK2A2 1832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.